| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| 424B3 | Form of prospectus reflecting facts events constituting substantive change from last form |
Registration Statements
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| S-8 | Securities offered to employees pursuant to employee benefit plans |
Registration Statements
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 424B3 | Form of prospectus reflecting facts events constituting substantive change from last form |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
